Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia

Lancet. 1990 Jun 9;335(8702):1360-3. doi: 10.1016/0140-6736(90)91242-3.

Abstract

Serum concentrations of apolipoprotein(a) were measured in patients with heterozygous familial hypercholesterolaemia. The levels in 47 patients were a median of 2.5 times higher than those in controls matched for age and sex (240 [range 25-1245] vs 97 [7-1040] mg/l). Among patients with familial hypercholesterolaemia apo(a) levels were higher in those with (n = 48) than in those without (n = 72) ischaemic heart disease (283 [18-1245] vs 144 [7-741] mg/l); both in univariate and multivariate analysis serum apo(a) was the most significant variable distinguishing between the groups. Despite reducing LDL cholesterol by 30%, treatment with cholestyramine or pravastatin did not reduce apo(a) levels in these patients. These findings support the concept that apo(a) concentration is a genetic trait predisposing to ischaemic heart disease and imply that it may be useful in the identification of familial hypercholesterolaemia patients at high risk of coronary disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anticholesteremic Agents / therapeutic use
  • Apolipoproteins A / blood*
  • Cholestyramine Resin / therapeutic use
  • Coronary Disease / blood*
  • Female
  • Heptanoic Acids / therapeutic use
  • Humans
  • Hyperlipoproteinemia Type II / blood*
  • Hyperlipoproteinemia Type II / complications
  • Hyperlipoproteinemia Type II / drug therapy
  • Male
  • Middle Aged
  • Naphthalenes / therapeutic use
  • Pravastatin
  • Receptors, LDL / drug effects

Substances

  • Anticholesteremic Agents
  • Apolipoproteins A
  • Heptanoic Acids
  • Naphthalenes
  • Receptors, LDL
  • Cholestyramine Resin
  • Pravastatin